Background Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein
(LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse …

Background The cardiovascular safety of testosterone-replacement therapy in middle-aged
and older men with hypogonadism has not been determined. Methods In a multicenter, …

… Drs Nicholls and Lincoff contributed equally to this article. … Dr Lincoff reported receiving
grants from AstraZeneca during the conduct of the study, and Esperion, Novartis, CSL, and …

Background Vorapaxar is a new oral protease-activated–receptor 1 (PAR-1) antagonist that
inhibits thrombin-induced platelet activation. Methods In this multinational, double-blind, …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Background Current guidelines for patients with moderate- or high-risk acute coronary
syndromes recommend an early invasive approach with concomitant antithrombotic therapy, …

Background—Appropriate treatment policies should include an accurate estimate of a
patient’s baseline risk. Risk modeling to date has been underutilized in patients with acute …

Background The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal
antiinflammatory drugs (NSAIDs), remains uncertain. Methods Patients who required …

ContextThe direct thrombin inhibitor bivalirudin has been associated with better efficacy and
less bleeding than heparin during coronary balloon angioplasty but has not been widely …

ContextIt is commonly suggested that more than 50% of patients with coronary heart disease
(CHD) lack any of the conventional risk factors (cigarette smoking, diabetes, hyperlipidemia…